Adrian Rawcliffe is the Chief Executive Officer of Adaptimmune, a biopharmaceutical company developing cell therapies for solid tumor cancers.
Adrian Rawcliffe is the Chief Executive Officer of Adaptimmune, a biopharmaceutical company developing cell therapies for solid tumor cancers. He is a founder of Adaptimmune and succeeded James Noble as CEO in 2024, having previously led the company through its clinical development and public listing phases.
Full founder directory · Investor directory · Company funding database · Fundraising library